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Abstract 
OBJECTIVES: The synchronous occurrence 
of carcinoma confined to the ovary and endo- 
metrium presents a diagnostic and therapeutic 
dilemma. These tumors have been variously 
staged as FIG0 Stage IIA ovarian carcinoma, 
Stage III endometrial carcinoma, or synchron- 
ous dual primary carcinomas. Accumulating 
evidence suggests such patients have a 
favorable outcome. This retrospective study 
was undertaken to review our experience with 
these fascinating tumors. METHODS: The 
clinical records and the pathologic jindings of 
16 patients with synchronous dual primary 
ovarian and endometrial carcinomas were 
reviewed. RESULTS: The median age was 51 
years. Abnormal uterine bleeding was the most 
common presenting symptom (70’%). All pa- 
tients had Stage I ovarian and endometrial car- 
cinomas. Fourteen patients (88%) had endo- 
metrioid carcinoma in both sites, while two pa- 
tients (12%) had dissimilar histology. For 15 pa- 
tients (94%), the grade of both tumors was 
identical. Only three (19’%) patients had 
myometrial invasion, with less than 50% in- 
volvement in each case. All patients underwent 
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surgical staging, I1 (70%) of whom received 
adjuvant radiation or chemotherapy. The five 
patients treated with surgery alone had Grade I 
endometrioid tumors. The only relapse oc- 
curred in a patient with a clear cell component 
in both sites. No patient has died of disease. 
CONCLUSIONS: Patients with synchronous 
dual primary carcinomas appear to have a more 
favorable prognosis than that expected with 
Stage IIA ovarian or Stage III endometrial car- 
cinoma (100% vs. 63’% or 42’% survival at 3 
years, respectively). The excellent survival for 
patients with Grade 1 dual endometrioid tumors 
treated with surgery alone suggests that adju- 
vant therapy may not be necessary for this 
sub-group. 
Keywords: Ovarian; Endometrial; Maligna- 
ncy; Synchronous. 
Introduction 
The synchronous occurrence of carcinoma 
in the ovary and the endometrium is uncom- 
mon. The incidence of endometrial carcinoma 
in women with ovarian carcinoma ranges 
from 4.5 to 300/o, with the highest frequency 
occurring with endometrioid ovarian car- 
cinoma [l-4]. Conversely, the incidence of 
ovarian carcinoma in women with endomet- 
rial carcinoma ranges from 2 to 8.5% [l-5]. 
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The appropriate staging of these cases is 
controversial. Various authors have suggested 
staging such lesions as FIG0 Stage IIA ovari- 
an carcinoma, Stage III endometrial car- 
cinoma, or synchronous primary carcinomas 
[6-l I]. Classification of these tumors as dual 
primary carcinomas is relatively straightfor- 
ward when the histology is dissimilar. How- 
ever, such a designation is more difficult when 
the histology is similar or identical. 
Evidence is accumulating that suggests 
women with dual primary carcinomas have a 
favorable outcome. The survival for women 
with dual endometrioid carcinomas has been 
reported as 66-iOO’% [6,8]. In contrast, the 5- 
year survival is 45% for women with Stage II 
ovarian carcinoma [12], and 33-36% for 
women with Stage III endometrial carcinoma 
[13,14]. 
The therapeutic approach to these patients 
varies. Some authors suggest that surgical 
management alone may be adequate for selec- 
ted patients [6,8,9], while others believe that 
adjuvant therapy is indicated [lo]. A wide 
variety of adjuvant therapies has been utiliz- 
ed, including radiation therapy, both external 
beam and brachytherapy, as well as a multi- 
tude of chemotherapy regimens. 
The purpose of this study was to review our 
experience with synchronous dual primary 
carcinomas of the ovary and endometrium. 
Materials and methods 
Twenty patients with the diagnosis of syn- 
chronous dual primary ovarian and en- 
dometrial carcinomas were treated by the 
Gynecologic Oncology Service at the Univer- 
sity of Michigan Medical Center from 
1980- 199 1. Four patients were excluded from 
analysis on review: three had intra-abdominal 
spread of tumor precluding accurate classif- 
ication as dual primary tumors, and one was 
lost to follow-up 1 month after initial surgery. 
The clinical records of the remaining 16 pa- 
tients were abstracted to obtain information 
regarding their age, gravity, menopausal 
status, hormonal replacement therapy, pres- 
entation, treatment and follow-up. The 
pathologic findings were reviewed with regard 
to histology, depth of invasion, grade and 
stage. 
The patients were divided into three groups 
according to the histology of the ovarian and 
endometrial tumors [6]. Group A consisted of 
patients with similar endometrioid ovarian 
and endometrial histology (Fig. la and b). 
Group B consisted of patients with non- 
endometrioid but similar ovarian and endo- 
metrial histology. Group C consisted of pati- 
ents with dissimilar ovarian and endometrial 
histology (Fig. 2a and b). 
All patients were re-staged according to 
surgical findings utilizing current FIG0 cri- 
teria [ 15,161. Staging was performed assuming 
the presence of synchronously occurring dual 
primary carcinomas. 
Statistical analysis was by chi-square test of 
homogeneity, with P < 0.05 considered signi- 
ficant. 
Results 
The median age at presentation was 51 
years (range: 39-65 yrs). Ten (63%) patients 
were post-menopausal, of which only two 
were on hormonal replacement therapy. 
There were 3 (19%) nulligravid women; the 
median gravity was 2.5 (range: O-6). The 
presenting complaint was abnormal bleeding 
in 10 (63%) patients, while 6 (37%) had a 
palpable adnexal mass. 
A total of 127 ovarian and 353 endometrial 
carcinomas were treated by our division dur- 
ing the study period. Synchronous occurrence 
of dual primary tumors occurred in 12.6% of 
the ovarian carcinoma patients and 4.5% of 
the endometrial carcinoma patients. 
All sixteen patients had Stage I ovarian 
carcinoma: eight (50%) were Stage IA, two 
were Stage IB (12%), and six were Stage IC 
(38%) (Table 1). Both patients with Stage IB 
tumors had identical histology in both 
ovaries. Five of the Stage IC patients had car- 
cinoma arising in a focus of surface en- 
dometriosis, while two, including one with 
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Fig. I. Simultaneous ovarian and endometrial carcinomas of similiar histology. Both the ovarian (a) and endometrial neoplasms 
(b) have an endometrioid histology, characterized by prominent glands lined by columnar cells with clear cytoplasm and stratifying, 
round to oval nuclei (magnification x 330). 
surface endometriosis, had intra-operative 
rupture of the ovarian cyst. The histology of 
the ovarian carcinoma was endometrioid in 
fifteen (94%) patients, two of which contained 
either a clear cell or adenosquamous compo- 
nent. The histology of the remaining car- 
cinoma was transitional cell carcinoma. 
Twelve lesions were Grade 1 (75X), three were 
Grade 2 (19X), and one was Grade 3 (6%). 
All sixteen patients had Stage I endometrial 
carcinoma: 13 (81%) were Stage IA and 3 
(19%) were Stage IB (Table 1). The histology 
of the endometrial carcinoma was en- 
dometrioid in 15 (94%) patients, one of which 
contained a clear cell component. The histol- 
ogy of the remaining carcinoma was mucin- 
ous. Thirteen lesions were Grade 1 (8 1%) and 
three were Grade 2 (19%). In 15 patients 
(94X), the endometrial tumor was the same 
grade as the ovarian tumor. Each patient with 
myometrial involvement had less than 50% in- 
vasion into the myometrium. 
Twelve (75%) patients had endometrioid 
ovarian and endometrial carcinomas and were 
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Fig. 2. Simultaneous ovarian and endometrial carcinomas of divergent histology. The ovarian carcinoma (a) is of a transitional type 
in which spindled cells surround a central fibrovascular core without prominent gland formation. In contrast, the endometrial car- 
cinoma (b) is comprised of glands lined by cells with uniform, rounded nuclei similar to Fig. I (magnification x 330). 
classified as Group A. One (6%) patient had 
identical endometrioid ovarian and endomet- 
rial carcinomas containing a clear cell compo- 
nent and was classified as Group B. The 
remaining two (12%) patients had dissimilar 
ovarian and endometrial carcinomas: a transi- 
tional cell carcinoma and an endometrioid 
ovarian carcinoma with an adenosquamous 
component, both in conjunction with endo- 
metrioid endometrial carcinoma. These pati- 
ents were classified as Group C. 
All patients underwent surgical staging, 
consisting of cytologic washings, total 
abdominal hysterectomy, bilateral salpingo- 
oophorectomy, omentectomy and pelvic lym- 
phadenectomy. Five (31%) patients were 
treated with surgery alone. One (6%) patient 
received a preoperative cesium implant. Three 
(19%) patients were treated with post-opera- 
tive intra-peritoneal 32P. Four (25%) patients 
received post-operative external beam radia- 
tion therapy, either whole abdomen [3] or 
whole abdomen and whole pelvis [ 11. Five 
(31%) patients were treated with various post- 
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operative chemotherapy regimens: carbopla- 
tin; cisplatin/cyclophosphamide; melphalan/ 
medroxyprogesterone acetate; 5flurouracil/ 
vinblastine/medroxyprogesterone acetate. 
The only recurrence (6%) occurred in the 
woman whose endometrioid ovarian and 
endometrial carcinomas each contained a 
clear cell component. She received cispla- 
tin/cyclophosphamide chemotherapy for pul- 
monary metastases 36 months after her initial 
surgery, followed by whole brain irradiation 
and leukovorin/FuDR/carboplatin chemo- 
therapy for brain metastases 12 months later. 
She is currently alive with disease 62 months 
after presentation. With a median follow-up 
of 39 months, no patient has died of disease. 
Discussion 
The results of this study suggest that pati- 
ents with synchronous dual primary ovarian 
and endometrial carcinomas have a favorable 
prognosis. The overall survival was loo%, 
with a median follow-up of 39 months. This is 
markedly better than the extrapolated 63% or 
42-65% 3-year survival for patients with 
Stage II ovarian [17] or Stage III endometrial 
carcinoma, respectively [ 13,141. 
The median age at presentation was 51 
years, comparable to previous reports in 
which the median age ranged from 41 to 54 
years [6,7,10,11]. Thus, it appears that pati- 
ents with dual primary carcinoma tend to be 
lo-20 years younger than their counterparts 
with ovarian or endometrial carcinoma, in 
whom the median age at presentation is ap- 
proximately 60 years [ 18,191. As expected 
given the early stage of the ovarian tumor, the 
majority of patients presented with abnormal 
bleeding from the endometrial tumor. 
Previous investigators have reported survi- 
val rates of 57-100% for Group A, with an 
average of 80% (Table 2) [6-lo]. The varia- 
tion in survival was attributed to variation in 
the depth of myometrial invasion [6-IO]. 
Patients with deeply invasive (> 2/3) tumors 
appeared to have a significantly worse prog- 
nosis than did those whose tumors were less 
Table 1. Clinical characteristics of patients with ovarian and endometrial carcinomas. 
Patient Ovary corpus Rx Status Months 
Stage Grade Hist. Stage Grade Hist. Inv. 
L.B. IC 1 E IA I E ti S, R’ NED 82 
M.B. IA 1 E, CC IA I E, CC 4 S, R’ AWD 62 
M.C. IA I E IA I E Q S NED 25 
UC. IA I E IA 1 M 6 S NED I9 
J.D. IA 2 E IA 2 E 6 S, R3 NED 3 
J.G. IB 1 E, AS IB I E < l/3 S NED 102 
G.H. IC I E IB 1 E < l/2 S, C NED I9 
L.K. IA I E IA 1 E 4 S, C NED 16 
J.K. IA I E IA I E 6 S NED 6 
J.E.K. IA 3 TC IA I E 4 S, C NED 42 
E.K. IB 2 E IB 2 E < 113 R*, S. C NED 143 
S.L. IC I E IA 1 E + R4 NED 82 
M.E. IC 1 E IA I E + S NED 84 
I.M. IC 1 E IA 1 E o S, R3, C NED I44 
J.M. IC I E IA 1 E & S. R4 NED 80 
J.Z. IA 2 E IA 2 E f$ S, R4 NED 42 
E, endometrioid; CC, clear cell; M, mutinous; AS, adenosquamous; TC, transitional cell carcinoma; S, surgery; R ‘, whole abdomen 
and whole pelvis irradiation; RZ, preoperative cesium irradiation; R3, whole abdomen irradiation; R4, intraperitoneal P3’; C, 
chemotherapy; NED, no evidence of disease; AWD, alive with disease. 
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Table 2. Survival. 






6 16 100 II 45 
7 I 100 4 25 
8 I3 77 2 100 
9 13 100 2 100 
10 23 57 IO 50 
Pearl I2 100 I 100 









Group A: Endometrioid ovarian and endometrial histology. 
Group B: Non-endometrioid but similar ovarian and en- 
dometrial histology. 
Group C: Dissimilar ovarian and endometrial histology. 
“P < 0.05 vs. Groups B and C. 
invasive (Table 3) [6-lo]. None of the pati- 
ents in the present study had deeply invasive 
tumors, possibly contributing to the excellent 
survival rate. 
In contrast, survival rates of 25- 100% have 
been reported for patients in Group B, with 
an average of 52% (Table 2) [6-lo]. Similarly, 
the reported survival rates for patients in 
Group C are 50- lOO%, with an average of 
53% (Table 2) [6-lo]. The worse prognosis in 
these patients, as compared with the patients 
in Group A, has been attributed to greater 
aggressiveness of the non-endometrioid histo- 
Table 3. Depth of invasion and survival. 
logic types, which often present with deep 
myometrial or ovarian hilar invasion [6- lo]. 
Although the results for Groups B and C from 
the present study are comparable to previous 
studies, the numbers are too small to draw 
any meaningful conclusions. 
The etiology of these carcinomas is uncer- 
tain. Several investigators have proposed that 
the extended Mullerian system, comprising 
the ovarian epithelium, fallopian tube, uterine 
corpus and cervix may respond as a single 
morphologic unit to produce primary carcin- 
omas in multiple sites [6,20]. Endometriosis 
has been considered a predisposing factor by 
some [11,21], but not all investigators [6,22]. 
Similarly, previous investigators have impli- 
cated estrogen exposure as a stimulus for 
malignant transformation [23], citing the well- 
documented association between estrogen 
exposure and the development of endometrial 
carcinoma [24]. 
Determining whether synchronously occur- 
ring ovarian and endometrial carcinomas rep- 
resent dual primary tumors or metastatic 
lesions from either site remains difficult and 
controversial. Several investigators have 
classified the lesions as dual primary tumors if 
the endometrial lesion was minimally in- 
vasive, well-differentiated, and less than 2 cm 
in diameter [2,25,26]. Some authors have sug- 
Reference Group A 
< 213 >2/3 
N Survival N Survival 
(‘A,) (‘%I) (‘%I) (I%>) 
6 I5 100 I 100 
7 I 100 
8 9 89 4 50 
9 IO 100 3 100 
IO I6 75 7 14 
Pearl I3 100 
Total 64 92” I5 47 
Group B 
<2/3 > 213 
N Survival N Survival 
(I%,) (I%,) (‘%I) (1%)) 
4 25 7 57 
4 25 
2 100 
5 80 5 20 
I 100 
I6 56 I2 42 
Group C 
< 213 > 213 
N Survival N Survival 
(1%)) (‘%I) (1%)) (‘K) 
4 75 5 40 
2 100 
3 67 I 100 
2 100 
II 82 6 50 
Group A: Endometrioid ovarian and endometrial histology. 
Group B: Non-endometrioid but similar ovarian and endometrial histology 
Group C: Dissimilar ovarian and endometrial histology. 
“P < 0.05 vs. Group A > 213. 
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gested that the presence of dissimilar 
histologic subtypes indicates the lesions are 
primary, rather than metastatic, tumors 
[ 11,271. Still others have utilized the histologic 
grade, classifying Grade 1 and 2 lesions as 
dual primary, and Grade 3 lesions as 
metastatic, tumors [21]. Finally, the excellent 
survival for these patients has been used to 
support classifying these lesions as dual pri- 
mary tumors [3,6,8,10]. All investigators 
agree that careful and extensive clinicopatho- 
logic evaluation is a prerequisite for accurate 
classificaton. 
The treatment of these tumors varies wide- 
ly. In the present study, survival was excellent 
following surgical therapy with or without 
adjuvant therapy. There were no recurrences 
in the patients with Grade 1 endometrioid 
tumors treated with surgery alone, supporting 
previous reports that suggest adjuvant ther- 
apy may not be necessary for patients in this 
subgroup [6,7,9]. In contrast, patients with 
higher grade ovarian tumors are usually 
treated with adjuvant irradiation or chemo- 
therapy [28], and this approach should be 
applied to such patients with ovarian and 
endometrial tumors. Finally, the non- 
endometrioid or dissimilar histologic types 
may be aggressive [6,8], and should be treated 
with adjuvant irradiation or chemotherapy. 
In conclusion, patients with synchronous 
dual primary ovarian and endometrial car- 
cinomas appear to have a favorable progno- 
sis. However, the currently available 
information is derived from small, retrospec- 
tive studies. The definitive answer to the ap- 
propriate staging and treatment of these 
fascinating tumors requires a multicenter, 
randomized prospective trial. 
References 
Anneger JF, Malkasian CID: Patterns of other neoplasm5 
in patients with endometrial carcinoma. Cancer 48: 856, 
1981. 
Scully RE: Tumours of ovary and maldeveloped gonads. 
Atlas of Tumour Pathology, Series II-Fast. 16. Armed 
Forces Institute of Pathology, Washington, 1980. 
Czernobilsky B, Silverman BD, Mikuta JJ: Endometrioid 


















Primary carcinomas 3 I I 
Klemi KJ, Gronoos M: Endometrioid carcinoma of the 
ovary. A clinicopathologic, histochemical, and electron- 
microscopic study. Obstet Gynecol 53: 572, 1979. 
Kottmeier HL: The diagnosis and treatment of ovarian 
malignancies. Arch Pathol 37: 51, 1965. 
Eifel P, Hendrickson M, Ross J, Ballon S, Martinez A, 
Kempson R: Simultaneous presentation of carcinoma 
involving the ovary and the uterine corpus. Cancer 50. 
163, 1982. 
Piura B, Glezerman M: Synchronous carcinomas of endo- 
metrium and ovary. Gynecol Oncol 33: 261, 1989. 
Zaino RJ, Unger ER. Whitney C: Synchronous car- 
cinomas of the uterine corpus and ovary. Gynecol Oncol 
19: 329, 1984. 
Jambhekar NA, Sampat MB: Simultaneous endometrioid 
carcinoma of the uterine corpus and ovary: A clinico- 
pathologic study of 15 cases. J Surg Oncol 37: 20, 1988. 
Montoya F, Martin M, Schneider J, Matia JC. 
Rodriguez-Escudero FJ: Simultaneous appearance of 
ovarian and endometrial carcinoma: a therapeutic 
challenge. Eur J Gynaecol Oncol 10: 135, 1989. 
Choo YC, Naylor B: Multiple primary neoplasms of the 
ovary and uterus. Int J Gynecol Obstet 20; 327, 1982. 
Richardson GS, Scully RE, Najamosama Nikrui, Nelson 
JH: Common epithelial cancer of the ovary. N Engl J Med 
312: 415, 1985. 
Greven KM, Curran WJ, Whittington R, Fanning J. 
Randall ME, Wilder J, Peters AJ: Analysis of failure pat- 
terns in stage HI endometrial carcinoma and therapeutic 
implications. Int J Radiat Oncol Biol Phys 17: 35. 1989. 
Grigsby PW, Perez CA, Kuske RR, Kao MS, Galakatos 
AE: Results of therapy, analysis of failures, and prognos- 
tic factors for clinical and pathological stage III adenocar- 
cinema of the endometrium. Gynecol Oncol27: 44, 1987. 
FIGO: Corpus cancer staging. Int J Gynecol Obstet 28: 
190, 2989. 
Staging Announcement: FIG0 Cancer Committee: 
Gynecol Oncol 25: 383, 1986. 
Annual report on the results of treatment in gynecologic 
cancer. Volume 21. Int J Gynecol Obstet 38: 249, 1992. 
Gloeckler-Ries LA, Hankey BF, Edwards BK: Cancer 
Statistics Review 1973-1987. National Cancer Institute. 
Division of Cancer Prevention and Control, 1990. 
Yanick R, Ries LG. Yates JW: Ovarian cancer in the 
elderly: An analysis of Surveillence, Epidemiolgy and End 
Results Program data. Am J Obstet Gynecol 154: 639, 
1986. 
Woodruff JD, Julian CG: Multiple malignancy in the 
upper genital tract. Am J Obstet Gynecol 103: 810, 1969. 
Cummings PA, Fox H, Langley FA: An electron micro- 
scopic study of the endometrioid adenocarcinoma of the 
ovary and a comparison of its tine structure with that of 
normal endometrium and adenocarcinoma of the endo- 
metrium. J Pathol 113: 165, 1979. 
Ulbright JM, Roth LM: Metastatic and independent 
cancers of the endometrium and ovary. A clinicopatho- 
loigc study of 34 cases. Hum Pathol 16: 28, 1985. 
Article 







Silverman BB, O’Neill RT, Mikuta JJ: Multiple malignant 
tumors associated with primary carcinoma of the ovary. 
Surg Gynecol Obstet 134: 244, 1972. 
Ziel HK: Estrogen’s role in endometrial cancer. Obstet 
Gynecol 60: 509, 1982. 
Kurman RJ, Craig JM: Endometrioid and clear cell car- 
cinoma of the ovary. Cancer 29: 1653, 1972. 
Dokerty MB: Primary and secondary ovarian adenoacan- 
thoma: Surg Gynecol Obstet 99: 392, 1954: 
Matlock DL, Salem FA, Charles EH, Savage EW: Syn- 
chronous multiple neoplasms of the upper female genital 
tract. Gynecol Oncol 13: 271, 1982. 
Ozals RF, Rubin SC, Dembo AJ, Robboy SJ: Epithelial 
ovarian cancer. In: Principles and Practice of Gynecologic 
Oncology. (eds WJ Hoskins, CA Perez, RC Young), pp. 
731-782. JB. Lippincott Co. Philadelphia, 1992. 
Address for reprints: 
M.L. Pearl 
Department of Obstetrics and Gynecology 
Medical Professional Building 
Rm. D2202-0718 
1500 E. Medical Center Drive 
University of Michigan Medical Center 
Ann Arbor, MI 48109-0718 
USA 
Int J Gynecol Obstet 43 
